---
title: Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma
description: Camrelizumab is a humanized monoclonal antibody (mAb) that specifically binds to programmed cell death receptor 1 (PD-1), being developed for the treatment of various cancer types including advanced hepatocellular carcinoma (HCC). The recommended dosage of camrelizumab is 200 mg every two weeks (Q2W) in combination with rivoceranib for HCC.
image: https://www.amadorbioscience.com/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-07-1.jpg
---

![amador bioscience-png](https://www.amadorbioscience.com/hs-fs/hubfs/Web/logo/amador%20bioscience-png.png?width=166&height=64&name=amador%20bioscience-png.png)

- [Bioanalysis and Biomarker Services](https://www.amadorbioscience.com/bioanalysis-lab-solutions)
- [Clinical Pharmacology](https://www.amadorbioscience.com/clinical-pharmacology-services)
- [Regulatory Affairs](https://www.amadorbioscience.com/regulatory-affairs)
- [Clinical Research Services](https://www.amadorbioscience.com/clinical-research-services)
- [About Us](https://www.amadorbioscience.com/about-amador-bioscience) 
    - [About Amador](https://www.amadorbioscience.com/about-amador-bioscience)

- [News](https://www.amadorbioscience.com/news)
- [Resources](https://www.amadorbioscience.com/blog)
- [Amador China](https://www.amadorbio.cn)

# Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma

Camrelizumab is a humanized monoclonal antibody (mAb) that specifically binds to programmed cell death receptor 1 (PD-1), being developed for the treatment of various cancer types including advanced hepatocellular carcinoma (HCC). The recommended dosage of camrelizumab is 200 mg every two weeks (Q2W) in combination with rivoceranib for HCC.

![Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma](https://www.amadorbioscience.com/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-07-1.jpg)\\

###### **BACKGROUND**

 

Camrelizumab is a humanized monoclonal antibody (mAb) that specifically binds to programmed cell death receptor 1 (PD-1), being developed for the treatment of various cancer types including advanced hepatocellular carcinoma (HCC). The recommended dosage of camrelizumab is 200 mg every two weeks (Q2W) in combination with rivoceranib for HCC.

 

![Camrelizumab_PPK_Poster_ASCPT2024_FINAL_logos 拷贝](https://www.amadorbioscience.com/hs-fs/hubfs/Camrelizumab_PPK_Poster_ASCPT2024_FINAL_logos%20%E6%8B%B7%E8%B4%9D.jpg?width=16800&height=9450&name=Camrelizumab_PPK_Poster_ASCPT2024_FINAL_logos%20%E6%8B%B7%E8%B4%9D.jpg)

 

## Want to learn more?

[![Talk to an Expert](https://no-cache.hubspot.com/cta/default/22807122/87da9502-b1f2-408c-afe6-0276c6108ea9.png)](https://cta-redirect.hubspot.com/cta/redirect/22807122/87da9502-b1f2-408c-afe6-0276c6108ea9)

![未标题-1](https://www.amadorbioscience.com/hs-fs/hubfs/%E6%9C%AA%E6%A0%87%E9%A2%98-1.png?width=210&height=80&name=%E6%9C%AA%E6%A0%87%E9%A2%98-1.png)

- Contact 
    - [Email Us](mailto:CBS_contact@crystalpharmatech.com)
    - +1-609-604-8303
    - [Contact Us](https://www.amadorbioscience.com/contact-amador)
- Our Services 
    - [Bioanalysis and Biomarker Services](https://www.amadorbioscience.com/bioanalysis-lab-solutions)
    - [Clinical Pharmacology](https://www.amadorbioscience.com/clinical-pharmacology-services)
    - [Regulatory Affairs](https://www.amadorbioscience.com/regulatory-affairs)
    - [Clinical Research Services](https://www.amadorbioscience.com/clinical-research-services)
- Information 
    - [About Us](https://www.amadorbioscience.com/about-amador-bioscience)
    - [Careers](https://www.crystalpharmatech.com/careers/)
    - [Events](https://www.crystalpharmatech.com/events/)
    - [News](https://www.amadorbioscience.com/news)

- [Privacy Policy](https://www.amadorbioscience.com/privacy-policy)
- [Terms & Conditions](https://www.amadorbioscience.com/terms-conditions)

By signing up, you agree to the [Privacy Policy](https://www.amadorbioscience.com/privacy-policy).

Copyright © 2026 Amador Bioscience, All rights reserved

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Amador Bioscience",
    "url" : "https://www.amadorbioscience.com/blog/author/amador-bioscience"
  },
  "dateModified" : "2024-07-09T07:04:53.456Z",
  "datePublished" : "2024-04-02T02:44:21.000Z",
  "headline" : "Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma",
  "image" : [ "https://www.amadorbioscience.com/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-07-1.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.amadorbioscience.com/blog/poppk-modeling-of-camrelizumab-in-patients-with-various-cancer-types-including-advanced-hepatocellular-carcinoma-ascpt",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.amadorbioscience.com/hubfs/Horizontal%20Amador%20logo-EN%20(1).png"
    },
    "name" : "Amador Bioscience"
  }
}
```